New cancer drug tested in people with advanced tumors
NCT ID NCT06457997
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was stopped early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth
Orlando, Florida, 32804, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT - San Antonio
San Antonio, Texas, 78229, United States
-
NEXT - Virginia
Fairfax, Virginia, 22031, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
University of Washington/Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can your own immune cells beat advanced cancer?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer